Developer of precision therapeutics for dry AMD and rare genetic diseases. The company's approach to drug discovery is genome-driven and multi-modal, i.e., therapeutics are targeted to specific genetic mutations, and are not limited to a single approach, and are tailored to the target. Founded in 2015, headquartered in Cambridge, United States. The company has raised $44.5M in funding at the series a stage. The team comprises 45 (Dec 31, 2022) employees. Gemini Therapeutics operates in the Rare Diseases, Genomics sectors. The company focuses on Metabolic Disorders, Therapeutics. Notable investors include Atlas Venture, Lightstone Ventures, Orbimed, Foresite Capital. The company has a team of 45 employees.
← All startups
Gemini Therapeutics
Series ADeveloper of precision therapeutics for dry AMD and rare genetic diseases. The company's approach to drug discovery is genome-driven and multi-modal, i.e., therapeutics are targeted to specific genetic mutations, and are not limited to a single approach, and are tailored to the target. Founded in 2015, headquartered in Cambridge, United States. The company has raised $44.5M in funding at the series a stage. The team…
About
Business model
Rare Diseases > Drugs > Metabolic Disorders,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > University of Edinburgh
Institutional investors
Atlas VentureLightstone VenturesOrbimedForesite Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.